Anti-cancer potential of MAPK pathway inhibition in paragangliomas-effect of different statins on mouse pheochromocytoma cells.

To date, malignant pheochromocytomas and paragangliomas (PHEOs/PGLs) cannot be effectively cured and thus novel treatment strategies are urgently needed. Lovastatin has been shown to effectively induce apoptosis in mouse PHEO cells (MPC) and the more aggressive mouse tumor tissue-derived cells (MTT)...

Full description

Bibliographic Details
Main Authors: Stephanie M J Fliedner, Tobias Engel, Nikoletta K Lendvai, Uma Shankavaram, Svenja Nölting, Robert Wesley, Abdel G Elkahloun, Hendrik Ungefroren, Angela Oldoerp, Gary Lampert, Hendrik Lehnert, Henri Timmers, Karel Pacak
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2014-01-01
Series:PLoS ONE
Online Access:http://europepmc.org/articles/PMC4028222?pdf=render
id doaj-790ee855c92542cf96f77d52906cb93d
record_format Article
spelling doaj-790ee855c92542cf96f77d52906cb93d2020-11-25T02:32:57ZengPublic Library of Science (PLoS)PLoS ONE1932-62032014-01-0195e9771210.1371/journal.pone.0097712Anti-cancer potential of MAPK pathway inhibition in paragangliomas-effect of different statins on mouse pheochromocytoma cells.Stephanie M J FliednerTobias EngelNikoletta K LendvaiUma ShankavaramSvenja NöltingRobert WesleyAbdel G ElkahlounHendrik UngefrorenAngela OldoerpGary LampertHendrik LehnertHenri TimmersKarel PacakTo date, malignant pheochromocytomas and paragangliomas (PHEOs/PGLs) cannot be effectively cured and thus novel treatment strategies are urgently needed. Lovastatin has been shown to effectively induce apoptosis in mouse PHEO cells (MPC) and the more aggressive mouse tumor tissue-derived cells (MTT), which was accompanied by decreased phosphorylation of mitogen-activated kinase (MAPK) pathway players. The MAPK pathway plays a role in numerous aggressive tumors and has been associated with a subgroup of PHEOs/PGLs, including K-RAS-, RET-, and NF1-mutated tumors. Our aim was to establish whether MAPK signaling may also play a role in aggressive, succinate dehydrogenase (SDH) B mutation-derived PHEOs/PGLs. Expression profiling and western blot analysis indicated that specific aspects of MAPK-signaling are active in SDHB PHEOs/PGLs, suggesting that inhibition by statin treatment could be beneficial. Moreover, we aimed to assess whether the anti-proliferative effect of lovastatin on MPC and MTT differed from that exerted by fluvastatin, simvastatin, atorvastatin, pravastatin, or rosuvastatin. Simvastatin and fluvastatin decreased cell proliferation most effectively and the more aggressive MTT cells appeared more sensitive in this respect. Inhibition of MAPK1 and 3 phosphorylation following treatment with fluvastatin, simvastatin, and lovastatin was confirmed by western blot. Increased levels of CASP-3 and PARP cleavage confirmed induction of apoptosis following the treatment. At a concentration low enough not to affect cell proliferation, spontaneous migration of MPC and MTT was significantly inhibited within 24 hours of treatment. In conclusion, lipophilic statins may present a promising therapeutic option for treatment of aggressive human paragangliomas by inducing apoptosis and inhibiting tumor spread.http://europepmc.org/articles/PMC4028222?pdf=render
collection DOAJ
language English
format Article
sources DOAJ
author Stephanie M J Fliedner
Tobias Engel
Nikoletta K Lendvai
Uma Shankavaram
Svenja Nölting
Robert Wesley
Abdel G Elkahloun
Hendrik Ungefroren
Angela Oldoerp
Gary Lampert
Hendrik Lehnert
Henri Timmers
Karel Pacak
spellingShingle Stephanie M J Fliedner
Tobias Engel
Nikoletta K Lendvai
Uma Shankavaram
Svenja Nölting
Robert Wesley
Abdel G Elkahloun
Hendrik Ungefroren
Angela Oldoerp
Gary Lampert
Hendrik Lehnert
Henri Timmers
Karel Pacak
Anti-cancer potential of MAPK pathway inhibition in paragangliomas-effect of different statins on mouse pheochromocytoma cells.
PLoS ONE
author_facet Stephanie M J Fliedner
Tobias Engel
Nikoletta K Lendvai
Uma Shankavaram
Svenja Nölting
Robert Wesley
Abdel G Elkahloun
Hendrik Ungefroren
Angela Oldoerp
Gary Lampert
Hendrik Lehnert
Henri Timmers
Karel Pacak
author_sort Stephanie M J Fliedner
title Anti-cancer potential of MAPK pathway inhibition in paragangliomas-effect of different statins on mouse pheochromocytoma cells.
title_short Anti-cancer potential of MAPK pathway inhibition in paragangliomas-effect of different statins on mouse pheochromocytoma cells.
title_full Anti-cancer potential of MAPK pathway inhibition in paragangliomas-effect of different statins on mouse pheochromocytoma cells.
title_fullStr Anti-cancer potential of MAPK pathway inhibition in paragangliomas-effect of different statins on mouse pheochromocytoma cells.
title_full_unstemmed Anti-cancer potential of MAPK pathway inhibition in paragangliomas-effect of different statins on mouse pheochromocytoma cells.
title_sort anti-cancer potential of mapk pathway inhibition in paragangliomas-effect of different statins on mouse pheochromocytoma cells.
publisher Public Library of Science (PLoS)
series PLoS ONE
issn 1932-6203
publishDate 2014-01-01
description To date, malignant pheochromocytomas and paragangliomas (PHEOs/PGLs) cannot be effectively cured and thus novel treatment strategies are urgently needed. Lovastatin has been shown to effectively induce apoptosis in mouse PHEO cells (MPC) and the more aggressive mouse tumor tissue-derived cells (MTT), which was accompanied by decreased phosphorylation of mitogen-activated kinase (MAPK) pathway players. The MAPK pathway plays a role in numerous aggressive tumors and has been associated with a subgroup of PHEOs/PGLs, including K-RAS-, RET-, and NF1-mutated tumors. Our aim was to establish whether MAPK signaling may also play a role in aggressive, succinate dehydrogenase (SDH) B mutation-derived PHEOs/PGLs. Expression profiling and western blot analysis indicated that specific aspects of MAPK-signaling are active in SDHB PHEOs/PGLs, suggesting that inhibition by statin treatment could be beneficial. Moreover, we aimed to assess whether the anti-proliferative effect of lovastatin on MPC and MTT differed from that exerted by fluvastatin, simvastatin, atorvastatin, pravastatin, or rosuvastatin. Simvastatin and fluvastatin decreased cell proliferation most effectively and the more aggressive MTT cells appeared more sensitive in this respect. Inhibition of MAPK1 and 3 phosphorylation following treatment with fluvastatin, simvastatin, and lovastatin was confirmed by western blot. Increased levels of CASP-3 and PARP cleavage confirmed induction of apoptosis following the treatment. At a concentration low enough not to affect cell proliferation, spontaneous migration of MPC and MTT was significantly inhibited within 24 hours of treatment. In conclusion, lipophilic statins may present a promising therapeutic option for treatment of aggressive human paragangliomas by inducing apoptosis and inhibiting tumor spread.
url http://europepmc.org/articles/PMC4028222?pdf=render
work_keys_str_mv AT stephaniemjfliedner anticancerpotentialofmapkpathwayinhibitioninparagangliomaseffectofdifferentstatinsonmousepheochromocytomacells
AT tobiasengel anticancerpotentialofmapkpathwayinhibitioninparagangliomaseffectofdifferentstatinsonmousepheochromocytomacells
AT nikolettaklendvai anticancerpotentialofmapkpathwayinhibitioninparagangliomaseffectofdifferentstatinsonmousepheochromocytomacells
AT umashankavaram anticancerpotentialofmapkpathwayinhibitioninparagangliomaseffectofdifferentstatinsonmousepheochromocytomacells
AT svenjanolting anticancerpotentialofmapkpathwayinhibitioninparagangliomaseffectofdifferentstatinsonmousepheochromocytomacells
AT robertwesley anticancerpotentialofmapkpathwayinhibitioninparagangliomaseffectofdifferentstatinsonmousepheochromocytomacells
AT abdelgelkahloun anticancerpotentialofmapkpathwayinhibitioninparagangliomaseffectofdifferentstatinsonmousepheochromocytomacells
AT hendrikungefroren anticancerpotentialofmapkpathwayinhibitioninparagangliomaseffectofdifferentstatinsonmousepheochromocytomacells
AT angelaoldoerp anticancerpotentialofmapkpathwayinhibitioninparagangliomaseffectofdifferentstatinsonmousepheochromocytomacells
AT garylampert anticancerpotentialofmapkpathwayinhibitioninparagangliomaseffectofdifferentstatinsonmousepheochromocytomacells
AT hendriklehnert anticancerpotentialofmapkpathwayinhibitioninparagangliomaseffectofdifferentstatinsonmousepheochromocytomacells
AT henritimmers anticancerpotentialofmapkpathwayinhibitioninparagangliomaseffectofdifferentstatinsonmousepheochromocytomacells
AT karelpacak anticancerpotentialofmapkpathwayinhibitioninparagangliomaseffectofdifferentstatinsonmousepheochromocytomacells
_version_ 1724816534028681216